Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|April 24, 2026

The BioPharm Brief: Innovation, Gene Therapy Momentum, and Next-Gen ADCs Lead Today’s Headlines

Listen
0:00 / 0:00

This episode of The BioPharm Brief covers innovation trends in biopharma hubs, a positive CHMP opinion for Novartis’ intrathecal gene therapy in spinal muscular atrophy, and early clinical data for a novel bispecific ADC in breast cancer. Key updates highlight regulatory momentum, emerging technologies, and next-generation oncology therapeutics.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping the biopharmaceutical industry. Today, we’re covering where innovation is happening across global biotech hubs, a new regulatory step forward for gene therapy in spinal muscular atrophy, and early clinical data on a next-generation antibody-drug conjugate in breast cancer.

We start with insights from the latest Ron Lanton Report, which takes a closer look at where biopharma innovation is thriving. The report points to a continued concentration of activity in established hubs like Boston and San Francisco, while also noting the rise of emerging regions driven by academic partnerships, venture funding, and specialized talent pools. The takeaway here is that innovation is no longer confined to a few legacy clusters—it’s becoming more distributed, though still highly competitive.

Next, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Novartis’ intrathecal formulation of onasemnogene abeparvovec for treating 5q spinal muscular atrophy in older patients. This expands on earlier gene therapy approaches by targeting a broader patient population and using an alternative route of administration. If approved, the therapy could represent a meaningful shift in how later-stage SMA is treated, particularly for patients who fall outside current eligibility criteria.

Finally, Alphamab Oncology is set to present Phase 1 data at the American Society of Clinical Oncology Annual Meeting for its investigational bispecific ADC, JSKN016, in HER2-negative breast cancer. Early findings suggest encouraging antitumor activity and a manageable safety profile in heavily pretreated patients. The therapy targets both TROP2 and HER3, reflecting a broader move toward multi-targeted approaches in oncology drug development.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • Innovation in biopharma is expanding beyond traditional hubs, though competition for talent and capital remains intense.
  • Regulators in Europe are backing new gene therapy approaches that could expand treatment access in spinal muscular atrophy.
  • Bispecific ADCs are emerging as a next wave in oncology, with early data pointing to improved targeting strategies.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more